Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Rank in Stocks #36454
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Share Price
$1.73
Last synced: 2025-06-17
Market Cap
$2.55M
Change (1 day)
-0.29%
Change (1 year)
-79.71%
Country
US
Trade Eiger BioPharmaceuticals, Inc. (EIGR)

Category

Healthcare
Number of shares outstanding for Eiger BioPharmaceuticals, Inc. (EIGR)
Number of shares outstanding as of December 2023: 1.48M
According to Eiger BioPharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 1.48M. At the end of December 2022 the company had 1.39M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Eiger BioPharmaceuticals, Inc. (EIGR) from 2016 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
2026 (TTM) 1.48M 0.22%
2023 1.48M 6.39%
2022 1.39M 22.64%
2021 1.13M 20.61%
2020 938.11K 23.51%
2019 759.52K 66.18%
2018 457.03K 57.09%
2017 290.93K 45.30%
2016 200.23K 0.00%
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 17,061.24%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 26,665.85%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 32,269.92%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 4,103.15%
NL